Omalizumab

stiri medicale; cazuri clinice
User avatar
Tasha
elite
elite
Posts: 5477
Joined: Sat Apr 29, 2006 2:23 pm

Omalizumab

Postby Tasha » Sat Jul 18, 2009 11:53 pm

July 16, 2009 — Results of an interim safety analysis of a clinical trial evaluating omalizumab (Xolair, Genentech/Novartis) in patients with moderate to severe asthma suggest that use of the drug may be associated with a disproportionate increase in the incidence of certain cardiovascular adverse events compared with control subjects, the US Food and Drug Administration (FDA) announced today.

The interim safety findings were from the ongoing Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS) trial, indicating increases in the incidence of ischemic heart disease, arrhythmias, cardiomyopathy and cardiac failure, pulmonary hypertension, cerebrovascular disorders, and embolic, thrombotic, and thrombophlebitic events in patients treated with omalizumab compared with control subjects, FDA announced.

The FDA is not recommending changes to safety labeling for for Xolair, and clinicians do not need to take their patients off the drug.
Sexy chicken.

User avatar
Phat Skidz
dɥɐʇ sʞıpz
Posts: 17832
Joined: Sun Jul 06, 2003 9:51 am

Re: Omalizumab

Postby Phat Skidz » Wed Jul 29, 2009 12:14 am

Interesant. Mulţumim.
SUNT BOȘOROGUL IMEDULUI


Return to “Medical news”

Who is online

Users browsing this forum: No registered users and 2 guests